Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more.
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are highly expressed in prostate tumors and exhibit greater prostate specificity than other prostate cancer antigens, reducing the risk of off-target immune responses. Researchers from Theravectys SA and Institut Pasteur reported preclinical efficacy data for Lenti-PROST-02, a novel lentiviral immunotherapy encoding immunogenic regions of PAP and PSA for the treatment of prostate cancer.
Core Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery and early clinical development.
Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway.
New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria.
Suggesting Replimune Group Inc.’s statistical analysis method inflated responses in the single-arm phase II Ignyte trial of RP-1 (suvolimogene oderparepvec), briefing documents ahead of the U.S. FDA’s Cellular, Tissue, and Gene Therapies advisory committee meeting on July 30 sent the company’s shares spiraling downward by about 38%.
Shanghai Jeyou Pharmaceutical Co. Ltd. has discovered new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, viral infection and autoimmune disease.
Shanghai Escugen Biotechnology Co. Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic drug potentially useful for the treatment of cancer.
Promatix Biosciences Ltd. has been awarded an Innovate UK Biomedical Catalyst grant to support development of its lead program, PBS-293-exatecan, a first-in-class EGFR x EphA2 cis-bispecific antibody-drug conjugate.
RSS
